Virdante Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Virdante Pharmaceuticals aims to improve the anti-inflammatory properties of antibodies with proprietary "sialic switch" technology developed by scientific founder Jeffrey Ravetch, MD, PhD, at Rockefeller University. If the process can be scaled up, Virdante thinks it will be possible to create products that are safer and more effective at treating inflammatory and autoimmune disorders.